Pages that link to "Q48088787"

The following pages link to Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications (Q48088787):

Displaying 50 items.

• Basic mechanisms of rTMS: Implications in Parkinson's disease (Q21202047) (← links)
• Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease (Q24040262) (← links)
• DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 (Q24305442) (← links)
• The role of oxidative stress in Parkinson's disease (Q24307946) (← links)
• The Preclinical Research Progress of Stem Cells Therapy in Parkinson's Disease (Q26744445) (← links)
• Structural Neuroimaging Markers of Cognitive Decline in Parkinson's Disease (Q26748709) (← links)
• What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease? (Q26767268) (← links)
• Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease (Q26773485) (← links)
• Neuroimaging studies of the striatum in cognition Part I: healthy individuals (Q26779302) (← links)
• Neuroimaging studies of striatum in cognition part II: Parkinson's disease (Q26779306) (← links)
• Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders (Q26826093) (← links)
• The role of the basal ganglia in learning and memory: insight from Parkinson's disease (Q26851807) (← links)
• Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease (Q26853225) (← links)
• Preservation of function in Parkinson's disease: what's learning got to do with it? (Q26853387) (← links)
• Upstream deregulation of calcium signaling in Parkinson's disease (Q27026384) (← links)
• Reward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson’s disease (Q27303483) (← links)
• Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats (Q27316872) (← links)
• Exploring Biological Motion Processing in Parkinson's Disease Using Temporal Dilation (Q27316956) (← links)
• Gray and White Matter Contributions to Cognitive Frontostriatal Deficits in Non-Demented Parkinson's Disease (Q27327538) (← links)
• Molecular imaging of movement disorders (Q28071336) (← links)
• How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum (Q28078491) (← links)
• The Network Model of Depression as a Basis for New Therapeutic Strategies for Treating Major Depressive Disorder in Parkinson's Disease (Q28078546) (← links)
• Parkinson's disease as a result of aging (Q28084395) (← links)
• Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa (Q28201762) (← links)
• The substantia nigra and its relations with the striatum in the monkey (Q28246714) (← links)
• 'Rejuvenation' protects neurons in mouse models of Parkinson's disease (Q28305585) (← links)
• The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study (Q28477041) (← links)
• Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS (Q28479192) (← links)
• The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats (Q28482094) (← links)
• Mitochondria in Alzheimer's disease (Q30310386) (← links)
• Encoding of sequence boundaries in the subthalamic nucleus of patients with Parkinson's disease. (Q30364799) (← links)
• Individual differences in beat perception affect gait responses to low- and high-groove music. (Q30368420) (← links)
• The effect of Parkinson's disease on interference control during action selection. (Q30371505) (← links)
• On the Complexity of Brain Disorders: A Symptom-Based Approach (Q30389213) (← links)
• Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine (Q30394681) (← links)
• Dose dependent dopaminergic modulation of reward-based learning in Parkinson's disease (Q30418659) (← links)
• Gray matter atrophy associated with extrapyramidal signs in the Lewy body variant of Alzheimer's disease. (Q30421996) (← links)
• The risky business of dopamine agonists in Parkinson disease and impulse control disorders (Q30425695) (← links)
• Implicit sequence learning in people with Parkinson's disease (Q30432855) (← links)
• Clinical applications of mesenchymal stem cells in chronic diseases (Q30437823) (← links)
• The basal ganglia in perceptual timing: timing performance in Multiple System Atrophy and Huntington's disease (Q30443884) (← links)
• Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia. (Q30483340) (← links)
• Automated quantitative gait analysis in animal models of movement disorders (Q30496179) (← links)
• The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment (Q30506209) (← links)
• Cortical control of saccades in Parkinson disease and essential tremor (Q30559517) (← links)
• Chronic spinal cord electrical stimulation protects against 6-hydroxydopamine lesions (Q30566773) (← links)
• Functional dynamics of primate cortico-striatal networks during volitional movements (Q30573767) (← links)
• Subthalamic deep brain stimulation in Parkinson׳s disease has no significant effect on perceptual timing in the hundreds of milliseconds range (Q30578248) (← links)
• New developments in the surgery for Parkinson's disease (Q30580687) (← links)
• Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease (Q30611520) (← links)